Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrik Schulze

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|June 1, 2013
What matters most in commercial success: first-in-class or best-in-class?Ulrik Schulze, Michael Ringel
Nature Reviews. Drug Discovery|February 6, 2020
Value of 2019 FDA approvals: back to the recent averageMathias Baedeker, Michael Ringel, Ulrik Schulze
Nature Reviews. Drug Discovery|February 3, 2019
2018 FDA approvals hit all time high - but average value slips againMathias Baedeker, Michael Ringel, Ulrik Schulze
Nature Reviews. Drug Discovery|January 16, 2021
2020 FDA approvals: momentum kept despite COVID-19, but value fallsMathias Baedeker, Michael Ringel, Ulrik Schulze
Nature Reviews. Drug Discovery|January 18, 2022
2021 FDA approvals: value driven by COVID-19 vaccinesMathias Baedeker, Michael S Ringel, Ulrik Schulze
Drug Discovery Today|May 25, 2013
Can emerging drug classes improve R&D productivity?Christoph Meier, Sarah Cairns-Smith, Ulrik Schulze
Nature Reviews. Drug Discovery|January 20, 2018
Market watch: 2017 FDA drug approvals: number rebounds but average value slipsMathias Baedeker, Michael Ringel, Valery Panier, et al.
Nature Reviews. Drug Discovery|February 3, 2017
Market watch: Value of 2016 FDA drug approvals: reversion to the mean?Ulrik Schulze, Michael Ringel, Valery Panier, et al.
Nature Reviews. Drug Discovery|October 19, 2013
Does size matter in R&D productivity? If not, what does?Michael Ringel, Peter Tollman, Greg Hersch, et al.
Nature Reviews. Drug Discovery|April 23, 2014
R&D productivity: on the comeback trailUlrik Schulze, Mathias Baedeker, Yen Ting Chen, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|June 1, 2013
What matters most in commercial success: first-in-class or best-in-class?Ulrik Schulze, Michael Ringel
Nature Reviews. Drug Discovery|February 6, 2020
Value of 2019 FDA approvals: back to the recent averageMathias Baedeker, Michael Ringel, Ulrik Schulze
Nature Reviews. Drug Discovery|February 3, 2019
2018 FDA approvals hit all time high - but average value slips againMathias Baedeker, Michael Ringel, Ulrik Schulze
Nature Reviews. Drug Discovery|January 16, 2021
2020 FDA approvals: momentum kept despite COVID-19, but value fallsMathias Baedeker, Michael Ringel, Ulrik Schulze
Nature Reviews. Drug Discovery|January 18, 2022
2021 FDA approvals: value driven by COVID-19 vaccinesMathias Baedeker, Michael S Ringel, Ulrik Schulze
Drug Discovery Today|May 25, 2013
Can emerging drug classes improve R&D productivity?Christoph Meier, Sarah Cairns-Smith, Ulrik Schulze
Nature Reviews. Drug Discovery|January 20, 2018
Market watch: 2017 FDA drug approvals: number rebounds but average value slipsMathias Baedeker, Michael Ringel, Valery Panier, et al.
Nature Reviews. Drug Discovery|February 3, 2017
Market watch: Value of 2016 FDA drug approvals: reversion to the mean?Ulrik Schulze, Michael Ringel, Valery Panier, et al.
Nature Reviews. Drug Discovery|October 19, 2013
Does size matter in R&D productivity? If not, what does?Michael Ringel, Peter Tollman, Greg Hersch, et al.
Nature Reviews. Drug Discovery|April 23, 2014
R&D productivity: on the comeback trailUlrik Schulze, Mathias Baedeker, Yen Ting Chen, et al.
Pageof 2